Chrodrimanin O (124), R (125), S (126), verruculide A (127), and chrodrimanin A (128), B (129), and H (130) exhibit protein tyrosine phosphatase 1B (PTP1B) inhibitory activity, with IC50 values ranging from 71.6 to 8.4 μM, suggesting potential for development as drugs targeting type 2 diabetes or obesity (Kong et al., 2017, Yamazaki et al., 2015). Here, PTPN1 is linked to obesity disorder.